▶ TESAMORELIN · SUBTOPIC · MECHANISM
TESAMORELIN Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Stabilized analog of human GHRH(1-44). Binds the GHRH receptor on pituitary somatotrophs. FDA-approved as Egrifta® for HIV-associated lipodystrophy under separate human-prescription label.
PHARMACOKINETIC HALF-LIFE
Reported half-life for TESAMORELIN: ~26 min plasma. Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
MECHANISM CATEGORIES
TESAMORELIN is tagged in 2 mechanism categories on GIGARESEARCH. Each category aggregates the broader pharmacology of related compounds.
The growth hormone axis is regulated by two complementary upstream signals: GHRH (stimulatory, from the hypothalamus, acting on the GHRH receptor on pituitary somatotrophs) and ghrelin (stimulatory, from the stomach, acting on the GHS-R1a). Research peptides target both arms: tesamorelin and CJC-1295 (GHRH analogs); ipamorelin, GHRP-6, and hexarelin (ghrelin-receptor agonists).
Lipolysis is the breakdown of triglycerides in adipose tissue, driven by hormone-sensitive lipase activation downstream of cAMP elevation. GH-axis peptides (tesamorelin) preferentially target visceral adipose. Glucagon-receptor agonism (the third arm of the triple-receptor incretin agonist) also drives hepatic lipid mobilization.
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with GIGARESEARCH evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Pooled Phase 3 (Falutz 2010, PMID 20554713; JAIDS 2010, PMID 20101189): -15.4% to -18% VAT vs placebo at 26 weeks.
Consistent dose-dependent IGF-1 increase across trials.
Off-label evidence limited. Theoretical applicability of GHRH-driven endogenous GH pulses to non-HIV-LD subjects is reasonable but not RCT-validated outside the approved label.
Stanley et al. (2019) reported reduced hepatic steatosis in HIV-NAFLD subjects on tesamorelin. Replicated subset findings; not yet a definitive Phase 3 outcome.
MECHANISM Q+A
▶ How does tesamorelin work?
Tesamorelin binds the GHRH receptor on anterior-pituitary somatotrophs and stimulates pulsatile growth-hormone release that approximates the natural diurnal pattern. The resulting GH elevation drives hepatic IGF-1 production. The net effect in lipodystrophic patients is preferential lipolysis of visceral adipose with little change in subcutaneous adipose.
▶ Tesamorelin vs CJC-1295 · what's different?
Both are GHRH analogs. Tesamorelin is a stabilized GHRH(1-44) · preserves the full natural 44-aa hormone sequence. CJC-1295 is a GHRH(1-29) analog with stabilizing substitutions; the With-DAC variant adds an albumin-tethering linker that extends half-life to a week. Tesamorelin is FDA-approved; CJC-1295 is research-use only.
▶ What is the half-life of tesamorelin?
Approximately 26 minutes plasma half-life. The N-terminal trans-3-hexenoic-acid modification protects against DPP-IV cleavage and extends half-life sufficiently for once-daily clinical dosing.
▶ Can tesamorelin be used for general body composition?
Off-label evidence is limited. Theoretical applicability to non-HIV-LD body composition research is reasonable given the GHRH-mediated mechanism, but no Phase 3 trials outside the approved HIV-LD label. This wiki does not recommend any human dose.
CITED LITERATURE
- Falutz J, Mamputu JC, Potvin D, et al.. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV patients with excess abdominal fat: pooled analysis of two phase 3 trials. J Clin Endocrinol Metab 2010. PMID 20554713. link
- Falutz J, Potvin D, Mamputu JC, et al.. Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with safety extension. J Acquir Immune Defic Syndr 2010. PMID 20101189. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19